Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 3.2% during the second quarter, Holdings Channel.com reports. The institutional investor owned 41,889 shares of the life sciences company’s stock after selling 1,400 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $15,421,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of ILMN. Norges Bank purchased a new position in shares of Illumina in the 4th quarter worth about $514,627,000. Thoroughbred Financial Services LLC boosted its holdings in shares of Illumina by 38,516.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after buying an additional 873,560 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Illumina by 107.1% in the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock worth $253,484,000 after buying an additional 421,953 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd boosted its holdings in shares of Illumina by 841.1% in the 1st quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 269,170 shares of the life sciences company’s stock worth $83,628,000 after buying an additional 240,569 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of Illumina by 3.7% in the 1st quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock worth $1,764,619,000 after buying an additional 200,114 shares during the last quarter. 89.82% of the stock is currently owned by institutional investors.
ILMN has been the topic of several recent research reports. Cowen upped their price objective on shares of Solaredge Technologies from $65.00 to $74.00 and gave the company an “outperform” rating in a report on Friday, July 12th. Bank of America set a $80.00 price target on Colgate-Palmolive and gave the company a “buy” rating in a research report on Friday, July 12th. Argus upped their price target on Canadian Pacific Railway to $265.00 and gave the company a “buy” rating in a research report on Thursday, July 18th. Canaccord Genuity upped their price target on Cogeco Communications from C$97.00 to C$104.00 and gave the company a “buy” rating in a research report on Friday, July 12th. Finally, OTR Global cut Illumina to a “positive” rating in a research report on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the stock. Illumina presently has a consensus rating of “Buy” and a consensus price target of $338.69.
In other news, Director Robert S. Epstein sold 5,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $310.44, for a total transaction of $1,552,200.00. Following the completion of the sale, the director now owns 8,256 shares of the company’s stock, valued at $2,562,992.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $311.77, for a total value of $38,659.48. Following the sale, the senior vice president now directly owns 8,086 shares of the company’s stock, valued at approximately $2,520,972.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,291 shares of company stock valued at $22,420,366. 0.38% of the stock is owned by insiders.
ILMN traded down $0.80 during midday trading on Friday, hitting $297.80. The stock had a trading volume of 14,932 shares, compared to its average volume of 1,568,098. The stock has a market capitalization of $43.60 billion, a P/E ratio of 52.06, a P/E/G ratio of 2.65 and a beta of 1.15. The company’s fifty day moving average is $341.09. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. Illumina, Inc. has a 1 year low of $268.62 and a 1 year high of $380.76.
Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.26. The business had revenue of $846.00 million during the quarter, compared to analyst estimates of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. Illumina’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.45 earnings per share. On average, research analysts expect that Illumina, Inc. will post 6.34 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: How to invest in blue-chip stocks
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.